SINA Corp (NASDAQ:SINA)‘s stock had its “neutral” rating reiterated by Zacks in a research report issued to clients and investors on Thursday. They currently have a $52.00 target price on the stock. Zacks‘s target price suggests a potential upside of 4.75% from the stock’s previous close. SINA Corp (NASDAQ:SINA) stock performance was -0.38% in last session and finished the day at $48.45. Traded volume was 1.54million shares in the last session and the average volume of the stock remained 2.80million shares. The beta of the stock remained 1.88. SINA Corp (NASDAQ:SINA) insider ownership is 4.81%.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on July 21 announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH, has entered into an exclusive marketing and supply agreement for BELVIQ® (lorcaserin HCl) with Teva Pharmaceutical Industries Limited’s local Israeli subsidiary, Abic Marketing Limited. Under the agreement, Arena granted Abic the rights to market and distribute BELVIQ in Israel for weight loss or weight management in obese and overweight patients, subject to regulatory approval by the State of Israel Ministry of Health (MOH). Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -0.51 percent to $4.85 Thursday on volume of 5.28million shares. The intra-day range of the stock was $4.80 to $4.91. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a market capitalization of $1.07billion.

FelCor Lodging Trust Incorporated (NYSE:FCH) today announced that it will release its second quarter financial results before the market opens on Thursday, July 31, 2014. Management will discuss the company’s operating results and outlook during a conference call at 10:00 a.m. (Central Time) that day. FelCor Lodging Trust Incorporated (NYSE:FCH)’s stock on July 24, 2014 reported a decrease of -1.70% to the closing price of $10.43. Its fifty two weeks range is $5.49 -$10.70. The total market capitalization recorded $1.30billion. The overall volume in the last trading session was 311,979.00million shares. In its share capital, FCH has 124.19million outstanding shares.

Anixter International (NYSE:AXE) VP William Galvin unloaded 2,000 shares of the company’s stock on the open market in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $97.26, for a total value of $194,520.00. Following the sale, the vice president now directly owns 46,278 shares in the company, valued at approximately $4,500,998. On Thursday, shares of Anixter International Inc. (NYSE:AXE) dropped -0.77% to close the day at $95.88. Company return on investment (ROI) is 13.90% and its monthly performance is recorded as -3.64%. Anixter International Inc. (NYSE:AXE) quarterly revenue growth is -1.22%.

Genomic Health (NASDAQ:GHDX) has received an average rating of “Hold” from the twelve ratings firms that are presently covering the stock, American Banking and Market News reports. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $29.38. Genomic Health, Inc. (NASDAQ:GHDX) stock performance was -3.06% in last session and finished the day at $26.65. Traded volume was 151,095.00million shares in the last session and the average volume of the stock remained 150.61K shares. The beta of the stock remained 0.54. Genomic Health, Inc. (NASDAQ:GHDX) insider ownership is 1.50%.